Often acts as a signal. Examples include oxytocin, GLP-1 and vasopressin. Drug versions may copy or modify those messages.
Independent research report · Updated September 8, 2026
Peptides are messages written in biology.
Some keep people alive. Some have transformed obesity care. Some are ordinary protein fragments sold as supplements. And some are experimental compounds marketed years ahead of the human evidence.
Educational research—not medical advice, a diagnosis, or a dosing guide.
THE CORE IDEANot one therapy. A molecular format.
A peptide is a chain of amino acidsThe small molecules that link together to form peptides and proteins.. Change the sequence and you change the message.
12%of U.S. adults said they currently used a GLP-1 drug in a 2025 KFF poll [S5]
26.5%of U.S. adults with diagnosed diabetes used injectable GLP-1s in 2024 [S6]
130+FDA-approved peptide drug products are designated reference listed drugs [S2]
11%of U.S. adults reported current GLP-1 use for weight loss in 2026 [S7]
01 · THE BASICS
Small chains.
Large effects.
Proteins and peptides use the same alphabet: 20 common amino acids. A peptide is the shorter note; a protein is usually the longer, folded machine. There is no single universal cutoff, but regulators and researchers often use length and manufacturing method to distinguish them.
“Peptide” therefore says little about benefit or risk. Insulin, a clinically tested prescription hormone, and BPC-157 sold online as “research use only” can both be called peptides. Their evidence and quality assurance are worlds apart.
Often performs structural, transport, immune or enzymatic work. The boundary with peptides is practical, not perfectly sharp.
A chemical bond joins one amino acid to the next. Digestive and cellular enzymes called proteases can cut these bonds.
INTERACTIVE · FOLLOW THE MESSAGE
How does a peptide actually work?
Select each stage. This simplified pathway describes receptor-targeting peptides such as GLP-1 medicines. Individual drugs can behave differently.
A message is made
Cells assemble amino acids into a precise chain. The order—not merely the ingredients—determines the message.
02 · THE PEPTIDE ATLAS
One name hides three very different worlds.
The full atlas separates approved medicines from experimental clinic compounds and food or cosmetic peptides. Evidence attaches to a specific molecule, dose, route, population and outcome—not to “peptides” as a category.
Evidence plus manufacturing controls
Insulin, semaglutide, tirzepatide, leuprolide, teriparatide, octreotide and others have specific approved indications, labels and post-market monitoring.
High confidence for labeled usesMechanism is not proof
BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, epitalon and similar compounds may have laboratory or animal findings without reliable human benefit data.
Low or very low confidenceDifferent claims, different evidence
Collagen hydrolysates are digested dietary peptides; copper peptides are cosmetic ingredients. They do not act like injectable prescription hormones.
Product- and outcome-specificTHE EVIDENCE RULE
A biological story can be plausible—and still be wrong in people.
1Cell study
→Can it affect isolated cells?
2Animal study
→Does it change an animal model?
3Human trial
→Does it help real patients?
4Replication
→Do independent studies agree?
5Approval & monitoring
Are benefits, risks and quality controlled?
The common internet error: jumping from steps 1–2 to a treatment claim. Most “healing peptide” enthusiasm lives in that gap.
03 · SAFETY BEFORE HYPE
What matters more than the word peptide.
Identity, purity, dose, route, sterility, evidence, interactions and the condition being treated determine risk. “Naturally occurring” is not a safety certificate.
Approved or unapproved?
FDA approval applies to a product and use—not a molecule-shaped idea. Compounded drugs are not FDA-approved.
What is actually in the vial?
Peptide impurities can be hard to characterize and may trigger immune responses. Sterility failures add infection risk.
What human evidence exists?
Ask for controlled human trials measuring a meaningful outcome—not testimonials, mechanistic diagrams or rodent healing.
Is the pathway appropriate?
Potent signals can create off-target effects. Growth, appetite, glucose, pigmentation and reproductive pathways are not isolated switches.
INTERACTIVE · 16 COMPOUNDS
Search the atlas.
Showing 16 of 16 entries
ApprovedMetabolismInsulin
Evidence +
- Why people take it
- Type 1 and type 2 diabetes
- How it works
- Signals cells to take up and store glucose and suppresses liver glucose output.
- What the evidence says
- A century of clinical use; multiple approved products and formulations.
- Bottom line
- Foundational, life-saving treatment when clinically indicated.
- Risks & unknowns
- Low blood sugar, weight gain, injection reactions; dosing errors can be dangerous.
Sources [S3]
ApprovedMetabolismSemaglutide
Ozempic · Wegovy · Rybelsus
Evidence +
- Why people take it
- Diabetes, chronic weight management and certain cardiovascular risk reduction
- How it works
- A GLP-1 receptor agonist that increases glucose-dependent insulin release, reduces appetite and slows gastric emptying.
- What the evidence says
- Large randomized trials; in STEP 1, mean weight change at 68 weeks was −14.9% versus −2.4% with placebo.
- Bottom line
- Powerful evidence for specific labeled uses—not a casual wellness compound.
- Risks & unknowns
- Mostly gastrointestinal; label also addresses pancreatitis, gallbladder disease, kidney injury, eye complications and a rodent thyroid-tumor warning.
ApprovedMetabolismTirzepatide
Mounjaro · Zepbound
Evidence +
- Why people take it
- Type 2 diabetes and chronic weight management
- How it works
- Activates both GIP and GLP-1 receptors, affecting insulin, glucagon, appetite and food intake.
- What the evidence says
- Large randomized programs support approved metabolic uses.
- Bottom line
- A major clinical medicine with product-specific benefits and risks.
- Risks & unknowns
- Gastrointestinal effects, gallbladder and pancreatic warnings, hypoglycemia with some drugs, and a rodent thyroid-tumor warning.
Sources [S14]
ApprovedReproductiveLeuprolide
Evidence +
- Why people take it
- Prostate cancer, endometriosis, fibroids and precocious puberty, depending on product
- How it works
- A GnRH agonist that initially stimulates, then suppresses, sex-hormone production with continuous exposure.
- What the evidence says
- Established prescription medicine with product-specific approvals.
- Bottom line
- Shows that a peptide can deliberately down-regulate a hormone system.
- Risks & unknowns
- Hot flashes, bone-density loss, mood and metabolic effects; indication and duration matter.
Sources [S3]
ApprovedBoneTeriparatide
PTH 1–34
Evidence +
- Why people take it
- Osteoporosis in selected people at high fracture risk
- How it works
- Intermittent parathyroid-hormone signaling stimulates bone formation.
- What the evidence says
- Randomized fracture-outcome evidence and approved labeling.
- Bottom line
- Timing changes the message: intermittent signaling builds bone; continuous excess can harm it.
- Risks & unknowns
- Dizziness, nausea, high calcium; use is limited to appropriate patients.
Sources [S3]
ApprovedSexual healthBremelanotide
PT-141 · Vyleesi
Evidence +
- Why people take it
- Acquired, generalized hypoactive sexual desire disorder in certain premenopausal women
- How it works
- Activates melanocortin receptors in the central nervous system.
- What the evidence says
- Approved for a narrow indication—not broadly for erectile function or libido enhancement.
- Bottom line
- The molecule can be legitimate while online off-label claims still outrun its label.
- Risks & unknowns
- Nausea, flushing, temporary blood-pressure increase and skin darkening.
Sources [S3]
ExperimentalRecoveryBPC-157
Evidence +
- Why people take it
- Marketed for tendon, gut and injury healing
- How it works
- Proposed effects on blood-vessel, nitric-oxide and growth-factor pathways come mainly from preclinical work.
- What the evidence says
- No reliable human efficacy evidence. A 2025 pilot reported IV exposure in only two healthy adults—far too small to show benefit or establish safety.
- Bottom line
- Interesting preclinical hypothesis; not a proven human recovery treatment.
- Risks & unknowns
- Unknown systemic effects, immune reactions, impurities, sterility and mislabeling. FDA proposed against 503A bulk-list inclusion in July 2026.
ExperimentalRecoveryTB-500
Thymosin beta-4 fragment
Evidence +
- Why people take it
- Marketed for wound and soft-tissue healing
- How it works
- A short fragment promoted as influencing cell migration and repair pathways.
- What the evidence says
- FDA reports no identified human exposure data for drug products containing this fragment.
- Bottom line
- Claims are substantially ahead of human evidence.
- Risks & unknowns
- Unknown benefit and safety, immunogenicity, aggregation, impurities and injection-related infection.
ExperimentalGrowthCJC-1295
Evidence +
- Why people take it
- Marketed for growth hormone, muscle gain, sleep and fat loss
- How it works
- A long-acting analogue intended to stimulate growth-hormone-releasing hormone receptors.
- What the evidence says
- Limited human data; no FDA-approved drug product.
- Bottom line
- A measurable hormone response is not proof of better recovery, muscle or longevity.
- Risks & unknowns
- FDA notes increased heart rate and systemic vasodilatory reaction among serious adverse events, plus impurity and immune risks.
Sources [S11]
ExperimentalGrowthIpamorelin
Evidence +
- Why people take it
- Marketed for growth hormone, body composition and recovery
- How it works
- A growth-hormone secretagogue acting at the ghrelin receptor.
- What the evidence says
- Some human pharmacology exists, but there is no approved anti-aging or bodybuilding use.
- Bottom line
- Hormone release is a surrogate marker, not a demonstrated patient benefit.
- Risks & unknowns
- FDA describes limited route-specific safety information and serious adverse events in an IV gastric-motility study.
Sources [S11]
ExperimentalLongevityMOTS-c
Evidence +
- Why people take it
- Marketed for metabolism, exercise and longevity
- How it works
- A mitochondrial-derived peptide studied as a metabolic signal.
- What the evidence says
- Primarily laboratory and animal work; FDA reports no identified human exposure data in drug products.
- Bottom line
- Scientifically intriguing, clinically unproven.
- Risks & unknowns
- Unknown human effects plus possible immune, purity and injection risks.
ExperimentalAppearanceMelanotan II
Evidence +
- Why people take it
- Marketed for tanning and sexual effects
- How it works
- A melanocortin-receptor agonist that can increase pigment production.
- What the evidence says
- No FDA-approved product; visible tanning does not establish safety.
- Bottom line
- A clear biological effect paired with uncontrolled safety and product quality.
- Risks & unknowns
- FDA cites case reports including priapism, severe neurologic syndromes and melanoma reports; causality varies by report.
Sources [S11]
ExperimentalCognitionSemax
Evidence +
- Why people take it
- Marketed for focus, neuroprotection and anxiety
- How it works
- A synthetic ACTH fragment proposed to affect neurotrophic and neurotransmitter pathways.
- What the evidence says
- Limited and geographically narrow human literature; no FDA-approved U.S. drug.
- Bottom line
- Insufficient evidence for routine cognitive enhancement.
- Risks & unknowns
- FDA says safety information is absent or limited for proposed compounded routes; immune and impurity risks remain.
Sources [S11]
ExperimentalLongevityEpitalon
Evidence +
- Why people take it
- Marketed for sleep, telomeres and anti-aging
- How it works
- A four-amino-acid peptide promoted as a pineal and telomere signal.
- What the evidence says
- No high-quality replicated evidence that it extends healthy human lifespan.
- Bottom line
- Longevity claims are not clinically established.
- Risks & unknowns
- Human safety information is inadequate; aggregation and peptide-related impurities may create immune risk.
Sources [S11]
ConsumerSupplementCollagen peptides
Hydrolyzed collagen
Evidence +
- Why people take it
- Marketed for skin, joints, nails and recovery
- How it works
- Dietary collagen is broken into amino acids and small peptides; some fragments may have signaling activity after absorption.
- What the evidence says
- Mixed. Earlier reviews reported modest skin or joint signals, while a 2025 meta-analysis found skin-aging benefits disappeared in non-industry-funded or higher-quality subsets.
- Bottom line
- Plausible modest effects for some outcomes; not injectable peptide therapy and not proven regeneration.
- Risks & unknowns
- Usually gastrointestinal or allergy concerns; product testing and source matter.
Sources [S16]
ConsumerCosmeticGHK-Cu
Copper peptide
Evidence +
- Why people take it
- Topical skin and hair products; also sold for injection
- How it works
- A copper-binding tripeptide studied in tissue remodeling and cell signaling.
- What the evidence says
- Cosmetic evidence is limited and product-specific. Injectable use is a separate, unapproved proposition.
- Bottom line
- Do not transfer topical plausibility to injected systemic claims.
- Risks & unknowns
- FDA cites limited human safety data and immune/impurity concerns for injectable routes.
Sources [S11]
04 · WHY PEOPLE TAKE THEM
A medical revolution overlaps with a self-experimentation boom.
Choose a goal to see how evidence changes across the same marketing category. This is a map of claims—not a recommendation engine.
The biggest evidence gap
BPC-157 and TB-500 dominate recovery marketing, but human injury-healing evidence is absent or inadequate.
- Common examples
- BPC-157 · TB-500 · GHK-Cu injection
- Evidence level
- Very low
- Primary caution
- Animal repair models do not establish human benefit, dose, safety or vial quality.
Patients treating diagnosed disease
Diabetes, obesity, osteoporosis, endocrine disorders, cancers, fertility conditions and rare diseases. The product, dose and outcome are defined.
Athletes and bodybuilders
Recovery, growth-hormone release and body composition drive interest. Many relevant substances are prohibited in tested sport. [S17]
Clinic patients and self-optimizers
Anti-aging, sleep, libido, cognition and “metabolic health” are often bundled into stacks despite sparse long-term evidence.
Supplement and skincare buyers
Collagen powders and copper-peptide cosmetics reach a much broader, lower-intensity market with different routes and claims.
05 · ESTABLISHED MEDICINE
The peptide era began long before TikTok.
Insulin entered clinical use in 1922. Later peptide drugs learned to pause puberty, stimulate bone formation, control hormone-sensitive cancers, prevent dangerous water loss and treat rare endocrine diseases.
Modern engineering can replace vulnerable amino acids, attach fatty acids, cyclize chains or use delivery devices to extend a peptide’s life. FDA notes that peptide products can share traits of both small-molecule drugs and biologics—and can create immune responses that must be assessed. [S1]
Common because peptide bonds are vulnerable to digestive enzymes and large water-soluble chains cross the gut wall poorly.
Formulation, absorption enhancers and molecular engineering protect selected products. “Oral” does not mean the molecule is a simple pill. [S15]
Some approved peptides use nasal delivery; absorption and technique can be variable.
Skin penetration is a major barrier. A topical cosmetic claim cannot be assumed to predict an injected systemic effect.
Microspheres, implants and depot formulations can turn short-lived signals into monthslong therapy.
CASE STUDY · THE GLP-1 BOOM
One gut peptide changed medicine—and peptide culture.
Natural GLP-1 is released after eating and is cleared within minutes. Engineered agonists survive far longer. They act in the pancreas, brain and gastrointestinal system, helping regulate glucose, appetite and food intake.
4×
Growth in reported current weight-loss use
Gallup measured current U.S. adult GLP-1 use for weight loss at 11% in 2026, up from 3% in 2024. Self-reported polling is not prescription auditing, but it captures how rapidly the category entered everyday life. [S7]
Multiple signals align
Appetite falls, satiety rises, glucose-dependent insulin response improves and gastric emptying slows. Different drugs and doses produce different outcomes.
Large, meaningful effects
In STEP 1, semaglutide plus lifestyle intervention produced a mean 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo. [S8]
Benefits do not erase tradeoffs
Nausea, vomiting, diarrhea and constipation are common. Labels address uncommon but serious problems and contraindications. Stopping therapy often leads to regain.
Use follows disease—and affordability
KFF found current use highest among adults 50–64 and reported affordability difficulty among many users. Coverage and indication shape who can stay on treatment. [S5]
COMPOUNDED ≠ GENERIC
The shortage-era gray market is narrowing.
FDA says compounded drugs are not FDA-approved, has reported dosing errors and hospitalizations with compounded semaglutide, and states semaglutide and tirzepatide were no longer on the shortage list in 2026. Its September update also says retatrutide and cagrilintide cannot lawfully be used in compounding, advises discarding multidose compounded sterile vials 28 days after first use, and warns patients not to use products that arrive warm or inadequately refrigerated. FDA also warns against products falsely implying sameness with approved brands. [S10] [S14] [S18] [S19]
CASE STUDY · BPC-157
The perfect anatomy of peptide hype.
It has a memorable origin story, impressive animal findings, a powerful promise—“heal faster”—and an online community of testimonials. What it does not yet have is reliable evidence that it improves injuries or gastrointestinal disease in humans.
THE SHORT ANSWER
Promising in animals is not proven in people.
Evidence confidence
Very low for efficacy
Preclinical repair signals
Rodent tendon, muscle, ligament, vascular and gut models are widely cited. These studies can generate hypotheses and dosing questions.
Convincing human outcomes
No replicated randomized human trials show faster tendon healing, better pain, improved function or gastrointestinal remission.
Two healthy volunteers
A 2025 publication reported short-term tolerability during IV infusion in two adults. That cannot demonstrate efficacy, detect uncommon harms or establish long-term safety. [S13]
FDA proposed “do not include”
At its July 2026 compounding advisory meeting, FDA proposed against adding BPC-157 free base or acetate to the 503A bulks list. The agency cited insufficient evidence plus quality and immune concerns. [S12]
RODENT TENDON≠HUMAN ATHLETE≠ONLINE VIAL
Each jump introduces uncertainty: biology may not translate, the treated condition may differ, and an internet product may not contain the identity, purity or dose on its label.
06 · COLLAGEN, COPPER & THE CONSUMER AISLE
Same word. Different proposition.
Collagen peptides are hydrolyzed pieces of food protein. The gut breaks much of them down further, though some small fragments may be absorbed. The claim is nutritional or signaling support—not receptor-level hormone replacement.
Copper peptide cosmetics face the opposite barrier: the product must cross the outer skin layers to reach its target. Evidence for a topical product cannot justify injectable GHK-Cu.
Some trials report modest hydration, elasticity or joint-pain improvements. A 2025 meta-analysis found apparent skin benefits overall but none in higher-quality or non-industry-funded subsets—an important bias signal. [S16]
Reasonable expectation: possible small benefit, not tissue regeneration.Mechanistic and small product studies are interesting, but formulations, stability and penetration vary. Cosmetic marketing often moves faster than comparative trials.
Reasonable expectation: uncertain, product-specific cosmetic effect.Injection changes exposure and risk. FDA specifically flags limited human safety information for injectable GHK-Cu and potential immune and impurity concerns. [S11]
Reasonable expectation: unknown benefit with materially higher risk.07 · THE REGULATORY MAP
“Prescribed” is not the same as “approved.”
U.S. compounding can serve patients whose needs cannot be met by an approved product. It is not a parallel shortcut around evidence, and a clinician’s prescription does not cause FDA to validate the compounded product.
FDA-approved drug
Reviewed for a specific indication, formulation, manufacturing process, label and benefit–risk balance. Subject to continuing safety surveillance.
Lawfully compounded drug
Prepared under applicable 503A or 503B conditions for a legitimate need. Not FDA-approved; quality oversight and circumstances differ.
Investigational drug
Studied under a clinical protocol with consent, monitoring and a defined question. Experimental does not mean available for routine treatment.
“Research use only” product
Not an approved human medicine. Online disclaimers do not establish identity, purity, sterility, legality or safety.
In July 2026, FDA’s advisory committee considered BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon for the 503A bulks list. FDA’s briefing proposed that the reviewed substances not be included. Advisory deliberation is not itself final approval or a blanket statement about every future research use. [S12] [S21]
08 · A PRACTICAL RISK CHECK
Before a vial, ask eight questions.
The questions become more important—not less—when a treatment is described as personalized, regenerative, natural or cutting-edge.
- 01
What exact molecule is it?
Full chemical identity, salt form and whether a brand or compounded preparation is being discussed.
- 02
Approved for what exact use?
A drug can be approved yet still promoted for an unsupported purpose.
- 03
What human outcome improved?
Pain, function, fractures, remission or survival—not merely a hormone or laboratory marker.
- 04
How many people, for how long?
Two volunteers can show immediate catastrophe did not occur twice; they cannot establish safety.
- 05
Who made and tested it?
Traceable licensed pharmacy, lot testing, sterility, potency and storage—not a certificate image supplied by an anonymous seller.
- 06
What are the known and theoretical risks?
Immune reactions, contamination, dosing error, pathway effects, interactions and disease-specific contraindications.
- 07
Is it prohibited in sport?
WADA prohibits many peptide hormones, growth factors, releasing factors and mimetics. [S17]
- 08
What is the better-established alternative?
Compare expected benefit, cost and uncertainty—not the peptide against doing nothing.
Marketing red flags
× “No side effects”× A multi-peptide stack on visit one× Animal studies presented as clinical proof× “Same as” an approved brand× Dosing advice from a seller× No named pharmacy or lot× Crypto-only or offshore checkout× Before/after photos without methods
INTERACTIVE · CLAIM CHECK
Can you spot the category errors?
Answer each claim. The explanation appears immediately; nothing is scored or stored.
Peptides are natural, so they are safer than ordinary drugs.
If a peptide raises a useful hormone, the promised benefit is proven.
Compounded means custom-made and FDA-approved.
An animal tendon-healing study proves human injury recovery.
All peptides have to be injected.
09 · PLAIN-ENGLISH GLOSSARY
Scientific words, decoded.
Agonist
A molecule that activates a receptor and produces a biological response.
Amino acid
A small molecule used as a building block for peptides and proteins.
Analogue
A modified version of a natural molecule designed to behave similarly, often with improved drug properties.
Bioavailability
The share of a dose that reaches circulation in an active form.
Biomarker
A measurable sign, such as a hormone level. Useful, but not automatically a health benefit.
Compounding
Preparing a drug for a patient or clinical need outside standard mass manufacturing, under specific legal conditions.
Half-life
How long it takes the amount of a substance in the body to fall by half.
Immunogenicity
The ability of a substance to trigger an immune response, including antibodies against the drug.
Indication
The disease, condition or use for which a drug is approved or prescribed.
Peptide bond
The chemical link joining one amino acid to the next.
Pharmacodynamics
What a drug does to the body—its effects and mechanism.
Pharmacokinetics
What the body does to a drug—absorption, distribution, metabolism and elimination.
Protease
An enzyme that cuts peptide bonds and breaks peptides or proteins apart.
Receptor
A cellular structure that recognizes a signal and starts a response.
Surrogate endpoint
A substitute measure expected to predict a real benefit, but which may not always do so.
503A / 503B
Two U.S. federal compounding frameworks: traditional patient-specific pharmacies and registered outsourcing facilities.
10 · FREQUENTLY ASKED QUESTIONS
Short answers to the big questions.
A peptide is a short chain of amino acids linked by peptide bonds. Many act as signals: they bind receptors and tell cells to change behavior. There is no universally fixed size cutoff, and the regulatory boundary between a peptide drug and a protein also depends on how it is made.
11 · METHOD & LIMITS
How this report judges a claim.
Evidence is graded by the question it can actually answer—not by how technical it sounds.
Separate categories
Approved medicine, compounded preparation, investigational compound, consumer supplement and cosmetic are never treated as interchangeable.
Prefer human outcomes
Randomized trials and clinically meaningful outcomes outrank cellular mechanisms, animal models and testimonials.
Follow the exact product
Evidence for one route, dose or formulation is not transferred to another without support.
Preserve uncertainty
“Not proven” is not “proven useless.” It means benefit, harm or both remain unresolved.
Important limits
This is a broad field guide, not a complete formulary or personalized risk assessment. Regulatory status changes. Polling measures reported use, not verified prescriptions. Adverse-event reports can identify signals but cannot by themselves prove causation. The report avoids dosing and sourcing instructions for unapproved compounds.
12 · SOURCE LIBRARY
Read the underlying evidence.
Primary regulators, drug labels, trial records and original research are prioritized. “Accessed September 8, 2026” applies to live regulator pages.
S1FDA — Clinical Pharmacology Considerations for Peptide Drug Products↗S2FDA — Immunogenicity Assessments in Peptides (130+ reference listed peptide drug products)↗S3Wang et al. — Therapeutic peptides: current applications and future directions↗S4Al Musaimi et al. — 2024 FDA TIDES harvest↗S5KFF — 2025 Health Tracking Poll on GLP-1 use and affordability↗S6CDC/NCHS — GLP-1 Injectable Use Among Adults With Diagnosed Diabetes: 2024↗S7Gallup — In U.S., GLP-1 Usage Reaches New High (2026)↗S8Wilding et al., NEJM — STEP 1 semaglutide obesity trial↗S9FDA — Wegovy prescribing information (2026)↗S10FDA — Compounding and the FDA: Questions and Answers↗S11FDA — Bulk substances for compounding that may present significant safety risks↗S12FDA — July 2026 Pharmacy Compounding Advisory Committee briefing document↗S13Lee et al. — Safety of Intravenous Infusion of BPC157 in Humans (two-adult pilot)↗S14FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss↗S15Gupta et al. — Oral delivery of therapeutic proteins and peptides↗S16Myung et al. — Effects of Collagen Supplements on Skin Aging: meta-analysis↗S17World Anti-Doping Agency — 2026 Prohibited List↗S18FDA — Dosing errors associated with compounded injectable semaglutide↗S19FDA — 2026 clarification after semaglutide and tirzepatide shortages stabilized↗S20ClinicalTrials.gov — NCT02637284 BPC-157 Phase I record↗S21FDA — July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting↗